<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Diagnostic Substances</title>
	<atom:link href="http://www.stockbloghub.com/category/diagnostic-substances/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYGN) Myriad Inks Deal with Cephalon</title>
		<link>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439</link>
		<comments>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:53:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97439</guid>
		<description><![CDATA[The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA).  Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study. Over the recent past, the company has entered into similar agreements with players such as Abbott (ABT), Astra Zeneca (AZN) and BioMarin Pharmaceuticals (BMRN) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad’s flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman&#8217;s risk for hereditary breast and ovarian cancer. Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Analyst Upgrades Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/01/abax-abaxis-analyst-upgrades-shares-to-neutral/87677</link>
		<comments>http://www.stockbloghub.com/2011/12/01/abax-abaxis-analyst-upgrades-shares-to-neutral/87677#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:16:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87677</guid>
		<description><![CDATA[Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (ABAX) to Neutral with a target price of $26.00. The company reported EPS of 15 cents in the quarter, surpassing the Zacks Consensus Estimate by 2 cents. On the other hand, net sales increased 13% year over year to $40 million and beat the Zacks Consensus Estimate of $38 million. The year-over-year growth was based on higher sales in both North America (up 8% to $31.9 million) and in the international market (up 39.9% to $8.0 million). The overall balanced revenue growth in both North America and in the international market was encouraging, especially amid a tough global macro-economic environment. Abaxis is executing well in its veterinary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/abax-abaxis-analyst-upgrades-shares-to-neutral/87677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Alere Takes Over Arriva Medical</title>
		<link>http://www.stockbloghub.com/2011/12/01/abax-alere-takes-over-arriva-medical/87806</link>
		<comments>http://www.stockbloghub.com/2011/12/01/abax-alere-takes-over-arriva-medical/87806#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87806</guid>
		<description><![CDATA[Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing supplies for patients residing at home. Florida-based Arriva had sales of about $21.5 million for the half year ending October 31, 2011. The company delivers diabetes supplies right to the patient’s home. It completes claim forms and bills Medicare as well as the supplemental insurance company for the patient. Alere paid about $65 million in cash to acquire Arriva, besides 806,452 restricted shares of its common stock. The deal is subject to working capital and various closing adjustments. By acquiring Arriva, Waltham-based Alere acquires fresh abilities to handle near-patient treatment. Alere’s expertise and product development efforts center around women’s health, infectious ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/abax-alere-takes-over-arriva-medical/87806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Analysts Cut Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588</link>
		<comments>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588#comments</comments>
		<pubDate>Sun, 10 Jul 2011 18:17:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78588</guid>
		<description><![CDATA[We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson &#38; Johnson (JNJ) announced in June 2011 that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year-end. SurModics receives royalties on sales of the product. The news impacted SurModics’ shares negatively. We too have slashed our earnings estimate for fiscal 2012 by $0.08 per share. However, management at SurModics is not too perturbed by the recent development since royalties from the sales of Cypher stent have been on the decline due to reduced sales of the product. Sales of the product have been on the decline due to increased completion from players like Abbott Labs (ABT), Medtronic Inc. (MDT) and Boston Scientific Corporation (BSX). Global sales of Cypher during the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Company News for July 6, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433</link>
		<comments>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433#comments</comments>
		<pubDate>Wed, 06 Jul 2011 15:47:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[EE]]></category>
		<category><![CDATA[El Paso Electric Company]]></category>
		<category><![CDATA[Energy Transfer Equity L.P.]]></category>
		<category><![CDATA[ETE]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Oppenheimer Holdings Inc]]></category>
		<category><![CDATA[OPY]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[Southern Union Company]]></category>
		<category><![CDATA[SUG]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[Western Union Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[Williams Companies Inc.]]></category>
		<category><![CDATA[WMB]]></category>
		<category><![CDATA[WU]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78433</guid>
		<description><![CDATA[•    Share prices of Southern Union Co. (NYSE:SUG) rose 4.21% to close at $42.07 after Energy Transfer Equity, L.P. (NYSE:ETE) increased its bidding amount by 21% to $5 billion for the company, beating William&#8217;s (NYSE:WMB) bid of $4.9 billion •    U.S. mining giant Peabody Energy Corp. (NYSE:BTU) was amongst a consortium selected by the  Mongolian Government  to develop the Tavan Tolgoi  coal mining project in the Gobi Desert •    Analysts of Wells Fargo (NYSE:WFC) opined that a medical journal report about Medtronic’s (NYSE:MDT) spine device will slow down sales. The report could also lead to investigations by federal regulators •    Analysts at Oppenheimer &#38; Co. (NYSE:OPY) initiated coverage on shares of Zalicus, Inc. (NASDAQ:ZLCS) with an &#8220;Outperform&#8221; rating and a target price of $4.00 •    Shares of Immucor, Inc. (NASDAQ:BLUD) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Purchased by TPG Capital for $1.9B</title>
		<link>http://www.stockbloghub.com/2011/07/06/blud-immucor-purchased-by-tpg-capital-for-1-9b/78440</link>
		<comments>http://www.stockbloghub.com/2011/07/06/blud-immucor-purchased-by-tpg-capital-for-1-9b/78440#comments</comments>
		<pubDate>Wed, 06 Jul 2011 15:45:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78440</guid>
		<description><![CDATA[Manufacturer and seller of automated systems and reagents, Immucor Inc. (BLUD) recently announced that it will be taken over by private equity group TPG Capital for $1.97 billion. As per the terms of the agreement, Immucor’s shareholders will receive $27 in cash for each share of the company, representing a premium of 30.2% over the closing price of the stock on July 1, 2011 and a premium of approximately 35.6% to Immucor&#8217;s average closing price over the last month. The deal is expected to be completed in the second half of 2011. Following this announcement, shares of Immucor surged 30% to $26.99 on Tuesday. The deal, however, is subject to regulatory approval and the support of the owners of a minimum of 84% of Immucor&#8217;s shares. TPG Capital will start ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/blud-immucor-purchased-by-tpg-capital-for-1-9b/78440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154</link>
		<comments>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78154</guid>
		<description><![CDATA[Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion into Europe. With respect to new products, Myriad aims to launch at least one new molecular diagnostic product each year. The company’s tenth product, slated for launch in the second half of 2011, will assist dermatopathologists in determining whether a patient’s mole is benign or a malignant melanoma. We are also encouraged by Myriad’s recent acquisition of Texas based, privately-held Rules-Based Medicine (RBM) for $80 million in cash. This deal would expand the company’s portfolio to take into its ambit psychiatric disorders, infectious diseases and inflammatory diseases. According to Myriad, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-bull-of-the-day/78160</link>
		<comments>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-bull-of-the-day/78160#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78160</guid>
		<description><![CDATA[Myriad Genetics&#8217; (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables the company to buyback shares, expand into new markets and introduce more products. Moreover, the acquisition of RMB will help diversify Myriad&#8217;s diagnostics portfolio and further strengthen its position in the companion diagnostics space. The company&#8217;s strategy of expanding into Europe is also encouraging. Although the economic environment has improved, any hiccup in the recovery process will be a dampener for the stock. Based on the strong growth potential of Myriad, we upgrade the stock to Outperform. MYRIAD GENETICS (MYGN): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-bull-of-the-day/78160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DDD) 3D Printing Comes of Age</title>
		<link>http://www.stockbloghub.com/2011/06/27/ddd-3d-printing-comes-of-age/77557</link>
		<comments>http://www.stockbloghub.com/2011/06/27/ddd-3d-printing-comes-of-age/77557#comments</comments>
		<pubDate>Mon, 27 Jun 2011 15:15:35 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADSK]]></category>
		<category><![CDATA[Autodesk Inc.]]></category>
		<category><![CDATA[DDD]]></category>
		<category><![CDATA[SCOLR Pharma Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77557</guid>
		<description><![CDATA[by Ryan Cole, Investment U Research Analyst Monday, June 27, 2011 Yet again science fiction is becoming science fact. This time, it’s the Star Trek replicator. Granted – we don’t have the technology to rearrange molecules as we wish yet, as they do on the USS Enterprise. Still – the 3D printer comes close. As long as the underlying material can be put into cartridges, a 3D printer can create anything you want. Believe it or not, the technology isn’t new. In fact, 3D printers of one sort or another have been around for 25 years. What’s different now? Instead of costing millions of dollars – and being available only to large manufacturing companies – 3D printing machines now cost as little as $1,000, and are about to become the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/ddd-3d-printing-comes-of-age/77557/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Gets Label Update for Feraheme</title>
		<link>http://www.stockbloghub.com/2011/06/26/amag-amag-pharmaceuticals-gets-label-update-for-feraheme/77485</link>
		<comments>http://www.stockbloghub.com/2011/06/26/amag-amag-pharmaceuticals-gets-label-update-for-feraheme/77485#comments</comments>
		<pubDate>Sun, 26 Jun 2011 16:41:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77485</guid>
		<description><![CDATA[AMAG Pharmaceuticals Inc. (AMAG) recently announced a label update for its lead drug Feraheme. Feraheme is an injectable drug for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients suffering from chronic kidney disease (CKD). The label was updated following approval by the US Food and Drug Administration (FDA) of the company&#8217;s Label Supplement submission which included additional post-marketing safety data. AMAG modified its Warnings and Precautions section to revise the language used to describe the hypersensitivity reactions. The revised label mentions that fatal and life-threatening serious hypersensitivity reactions, including anaphylactic-type reactions, have been reported in patients who have received Feraheme. The Contraindications section was also modified to remove language relating to evidence of iron overload and anemia not caused by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/amag-amag-pharmaceuticals-gets-label-update-for-feraheme/77485/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/06/21/srdx-surmodics-incorporated-bull-of-the-day-2/76905</link>
		<comments>http://www.stockbloghub.com/2011/06/21/srdx-surmodics-incorporated-bull-of-the-day-2/76905#comments</comments>
		<pubDate>Tue, 21 Jun 2011 13:25:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76905</guid>
		<description><![CDATA[In June 2011, SurModics, Inc. (SRDX) received a blow when Johnson &#38; Johnson announced that it will stop manufacturing Cypher stents by year end, as SurModics receives royalties on sales of the product. However, we believe the impact of the blow will not be very severe, and that the current price represents an attractive entry point for long-term investors. We have increased our fiscal 2011 earnings estimate by $0.14 per share to $0.16. This is within the guidance range of $0.13-$0.26 provided by the company. We have also upped our fiscal 2012 estimates to $0.41 from $0.20. We believe that if the company continues to deliver strong results in the coming quarters then the increased projection will be achieved easily. We believe that investors should be more concerned about the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/srdx-surmodics-incorporated-bull-of-the-day-2/76905/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AKRX) Company News for June 07, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683</link>
		<comments>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683#comments</comments>
		<pubDate>Tue, 07 Jun 2011 16:57:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Akorn Inc]]></category>
		<category><![CDATA[AKRX]]></category>
		<category><![CDATA[AMED]]></category>
		<category><![CDATA[Amedisys Inc.]]></category>
		<category><![CDATA[BAP]]></category>
		<category><![CDATA[Coventry Health Care Inc.]]></category>
		<category><![CDATA[Credicorp Limited]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CVH]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[Exelixis Inc]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LOW]]></category>
		<category><![CDATA[Lowe's Companies Inc.]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75683</guid>
		<description><![CDATA[•    Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011 •    According to Canaccord Genuity, data from a trial of Exelixis, Inc&#8217;s (NASDAQ:EXEL) cancer-drug candidate could possibly worsen its regulatory strategy •    According to the Wall Street Journal, Novartis AG (NYSE:NVS) could possibly opt out from the buying race for medical test manufacturer Gen-Probe Inc (NASDAQ:GPRO) •    Merge Healthcare Inc (NASDAQ:MRGE) announced plans to buy Ophthalmic Imaging Systems (OTC:OISI) for a deal worth $30.3 million in stock •    U.S.-listed shares of Peruvian metal producer Southern Copper Corp. (NYSE:SCCO) declined 11.35%, after a former army rebel won Peru&#8217;s presidential elections •    Raymond James Financial Inc. downgraded Credicorp Ltd (NYSE:BAP) , the Peruvian financial-services firm from &#8220;Outperform&#8221; to &#8220;Underperform&#8221; rating •    ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/07/akrx-company-news-for-june-07-2011-corporate-summary/75683/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VIVO) FDA OKs Meridian C. Difficile Test</title>
		<link>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020</link>
		<comments>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020#comments</comments>
		<pubDate>Fri, 13 May 2011 20:25:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VIVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74020</guid>
		<description><![CDATA[Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based company’s portfolio of C. difficile tests and underscores its sustained commitment to bring out breakthrough products for the detection of C. difficile. Premier GDH has been marketed in Europe since October 2010. C. difficile is a highly drug-resistant bacterium which exists in the environment in spore (or inactive) form and produces a toxin that causes diarrhea and more serious intestinal conditions such as colitis. C. difficile spores are frequently found in hospitals, nursing homes and extended care facilities. Although spores cannot cause infection directly, they transform into the active (or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Alere Quarterly Earnings Beats Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/04/abax-alere-quarterly-earnings-beats-estimates/73155</link>
		<comments>http://www.stockbloghub.com/2011/05/04/abax-alere-quarterly-earnings-beats-estimates/73155#comments</comments>
		<pubDate>Wed, 04 May 2011 17:04:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73155</guid>
		<description><![CDATA[Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported first-quarter fiscal 2011 adjusted earnings per share of 61 cents, beating the corresponding Zacks Consensus Estimate of 57 cents while trailing the year-ago earnings from continuing operations of 64 cents a share. Reported net income was about $8.1 million (or 9 cents per share) in the first quarter compared with $9 million (11 cents per share) in the prior-year period, down 10% year over year. Reported net income in the most recent quarter contains, among other items, a gain of $19.6 million emanating from the disposition of the nutritional segment. Revenues Net revenues were $582.5 million in the reported quarter, up 13% year over year, surpassing the Zacks Consensus Estimate of $562 million. On a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/abax-alere-quarterly-earnings-beats-estimates/73155/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Analyst Increases Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/05/04/srdx-surmodics-analyst-increases-shares-to-outperform/73179</link>
		<comments>http://www.stockbloghub.com/2011/05/04/srdx-surmodics-analyst-increases-shares-to-outperform/73179#comments</comments>
		<pubDate>Wed, 04 May 2011 16:49:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73179</guid>
		<description><![CDATA[We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Our target price on the stock is $18.00. The company delivered strong results in the second quarter of fiscal 2011 outshining the Zacks Consensus Estimate on both revenues and earnings fronts. Adjusted earnings in the quarter came in at $0.08 per share, well ahead of break-even earnings suggested by the Zacks Consensus Estimate. Adjusted revenues came in at $17.4 million, beating the Zacks Consensus Estimate by $2.4 million. The impressive showing prompted the company to raise the revenues and earnings guidance for fiscal 2011. SurModics expects to end fiscal 2011 with revenues in the range of $63 million-$68 million, as against the previously forecasted range of $55 million-$63 million. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/srdx-surmodics-analyst-increases-shares-to-outperform/73179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/05/04/srdx-surmodics-incorporated-bull-of-the-day/73198</link>
		<comments>http://www.stockbloghub.com/2011/05/04/srdx-surmodics-incorporated-bull-of-the-day/73198#comments</comments>
		<pubDate>Wed, 04 May 2011 16:40:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73198</guid>
		<description><![CDATA[We are upgrading SurModics Inc. (SRDX) to Outperform from Neutral following its strong showing in the second quarter of fiscal 2011. Adjusted earnings in the quarter came in at $0.08 per share, well ahead of break-even earnings suggested by the Zacks Consensus Estimate. Following the strong showing, the company raised its revenues and earnings projections for fiscal 2011. We have also raised our earnings estimates for fiscal 2011 and fiscal 2012. Our fiscal 2011 earnings estimates are within the company&#8217;s projected range. The efforts made by the company to revive itself after delivering below-par results in the past few quarters encourage us. Over the last five years, SurModics shares have traded in a range of 14.3x to 65.8x. Our target price of $18.00 is based on 43.9x our fiscal 2012 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/srdx-surmodics-incorporated-bull-of-the-day/73198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PBIO) Pressure BioSciences and KeraFAST Sign Worldwide E-Commerce Distribution Deal</title>
		<link>http://www.stockbloghub.com/2011/05/03/pbio-pressure-biosciences-and-kerafast-sign-worldwide-e-commerce-distribution-deal/73021</link>
		<comments>http://www.stockbloghub.com/2011/05/03/pbio-pressure-biosciences-and-kerafast-sign-worldwide-e-commerce-distribution-deal/73021#comments</comments>
		<pubDate>Tue, 03 May 2011 18:11:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73021</guid>
		<description><![CDATA[Grant Zeng, CFA PBIO and KeraFAST Sign Worldwide E-Commerce Distribution Deal On May 3, 2011, Pressure BioSciences, Inc. (PBIO) and KeraFAST LLC announced that they have entered into a non-exclusive, worldwide distribution agreement covering several of PBIO’s new sample preparation products. These products include the recently released The SHREDDER SG3 Extraction System; the novel MicroTube, MicroCap, and PCT Shredder sample processing tubes; and proprietary kits for the preparation of samples for DNA, RNA, protein, and lipid analysis. KeraFAST is a leading vendor of life sciences tools in the rapidly growing area of research products distribution through e-commerce channels. KeraFAST is committed to providing the next generation of research tools to life science laboratories worldwide. KeraFAST is an emerging leader in the application of FASTCell™ keratin protein technologies for cell culture ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/pbio-pressure-biosciences-and-kerafast-sign-worldwide-e-commerce-distribution-deal/73021/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing</title>
		<link>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983</link>
		<comments>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:13:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70983</guid>
		<description><![CDATA[Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total revenue. This test provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing woman&#8217;s risk of hereditary breast and ovarian cancers. Under the agreement, the company will carry out Bracanalysis test to identify the presence of germline mutations in the patients prior to enrollment in the study. Accordingly, it will provide standard test reports to the clinicians. Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRIB) Trinity Biotech &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/03/17/trib-trinity-biotech-bull-of-the-day-2/68396</link>
		<comments>http://www.stockbloghub.com/2011/03/17/trib-trinity-biotech-bull-of-the-day-2/68396#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:05:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68396</guid>
		<description><![CDATA[Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected to launch in Europe and the U.S. in 2011. Development of several new POC tests is ongoing, the fruits of which should be realized in 2012. TRIB has also just announced a share buyback program and dividend. Management has a recent history of under-promising and over-delivering. We are maintaining our Outperform rating. Our price target has moved from $9.90 to $10.80. TRINITY BIOTECH (TRIB): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/trib-trinity-biotech-bull-of-the-day-2/68396/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TRIB) Trinity Biotech &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/03/13/trib-trinity-biotech-bull-of-the-day/68331</link>
		<comments>http://www.stockbloghub.com/2011/03/13/trib-trinity-biotech-bull-of-the-day/68331#comments</comments>
		<pubDate>Sun, 13 Mar 2011 18:49:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68331</guid>
		<description><![CDATA[Since its Q2 2010 clinical lab coag divestiture, Trinity Biotech (TRIB) has slashed operating costs and begun pumping its huge and growing cash balance into higher growth segments. Expectations are high for the PDX instrument, expected to launch in Europe and the U.S. in 2011. Development of several new POC tests is ongoing, the fruits of which should be realized in 2012. TRIB has also just announced a share buyback program and dividend. Management has a recent history of under promising and over delivering. We are maintaining our Outperform rating. Our price target has moved from $9.90 to $10.80. TRINITY BIOTECH (TRIB): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/13/trib-trinity-biotech-bull-of-the-day/68331/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2010/09/14/srdx-surmodics-analyst-maintains-neutral-rating-on-shares/51392</link>
		<comments>http://www.stockbloghub.com/2010/09/14/srdx-surmodics-analyst-maintains-neutral-rating-on-shares/51392#comments</comments>
		<pubDate>Tue, 14 Sep 2010 13:16:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[RBS]]></category>
		<category><![CDATA[Royal Bank of Scotland Group plc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=51392</guid>
		<description><![CDATA[SurModics (SRDX), headquartered in Eden Prairie, Minnesota, is a provider of surface modification and drug delivery technologies to the healthcare industry. Following the changes in operational structure affected in 2008, the company currently operates through the following business units: cardiovascular, ophthalmology, SurModics pharmaceuticals (constituting the &#8220;therapeutic&#8221; segment) and In Vitro Technologies (diagnostics). Surmodics performed disappointingly in the most recent quarter. Earnings came in at $0.11 per share, short of the year-ago earnings by $0.09. We are encouraged by SurModics’ license agreement with Australian company Clinuvel Pharmaceuticals. The deal allows SurModics’ pharmaceuticals unit to license some of its biodegradable polymer implant technology to Clinuvel. The market opportunity for Clinuvel&#8217;s afamelanotide for ultraviolet (UV) related disorders being evaluated by the company is estimated by the Royal Bank of Scotland (RBS) to exceed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/14/srdx-surmodics-analyst-maintains-neutral-rating-on-shares/51392/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Signs Deal With Australian company Clinuvel Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2010/07/11/srdx-surmodics-signs-deal-with-australian-company-clinuvel-pharmaceuticals/43083</link>
		<comments>http://www.stockbloghub.com/2010/07/11/srdx-surmodics-signs-deal-with-australian-company-clinuvel-pharmaceuticals/43083#comments</comments>
		<pubDate>Sun, 11 Jul 2010 14:21:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angiotech Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANPI]]></category>
		<category><![CDATA[RBS]]></category>
		<category><![CDATA[Royal Bank of Scotland Group plc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43083</guid>
		<description><![CDATA[Recently, SurModics Inc. (SRDX) inked a licensing deal with Australian company Clinuvel Pharmaceuticals Limited. The deal allows SurModics’ pharmaceuticals unit, which provides proprietary polymer-based drug delivery technologies to companies developing advanced pharmaceutical products, to license some of its biodegradable polymer implant technology to the Melbourne-based company. The technology is used for treating sun-induced skin disorders. The clauses of the deal were undisclosed. The two companies have been working together to develop Clinuvel&#8217;s proprietary sustained release SCENESSE (afamelanotide) implant formulation for many years. The formulation is being developed as a preventive treatment for ultraviolet (UV) and light-related dermatological deficiencies. The implant is being studied for treating a range of dermatological disorders not only in Australia but also in Europe. SurModics’ biodegradable polymer drug delivery technology permits afamelanotide to be released in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/11/srdx-surmodics-signs-deal-with-australian-company-clinuvel-pharmaceuticals/43083/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PBIO) Pressure Biosciences&#8217; Technology on Display at Harvard Medical School Symposium</title>
		<link>http://www.stockbloghub.com/2010/05/24/pbio-pressure-biosciences-technology-on-display-at-harvard-medical-school-symposium/37870</link>
		<comments>http://www.stockbloghub.com/2010/05/24/pbio-pressure-biosciences-technology-on-display-at-harvard-medical-school-symposium/37870#comments</comments>
		<pubDate>Tue, 25 May 2010 03:19:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37870</guid>
		<description><![CDATA[Harvard Medical School Symposium On Friday, May 21, 2010, Harvard Medical School will host a symposium on the applications of ultra-high pressure in biotechnology. The full-day program focusing on the use of cycled ultra-high pressure (pressure cycling technology, or “PCT&#8221;) should highlight significant advancements in diagnostic and therapeutic medicine. Presenters include fifteen of the world’s leading scientists from academia, government, and industry discussing applications and recent scientific breakthroughs using this powerful platform. At the center of the discussion will be technology developed by Pressure Biosciences (PBIO), a small biotechnology company located near Boston, MA. Pressure Bio has created a proprietary PCT that uses rapid cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions. Advantages of PCT include a high dress of precision, reproducibility, convenience, speed, and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/pbio-pressure-biosciences-technology-on-display-at-harvard-medical-school-symposium/37870/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/05/23/mygn-myriad-genetics-bear-of-the-day-2/37635</link>
		<comments>http://www.stockbloghub.com/2010/05/23/mygn-myriad-genetics-bear-of-the-day-2/37635#comments</comments>
		<pubDate>Mon, 24 May 2010 04:26:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37635</guid>
		<description><![CDATA[Myriad Genetics Inc.&#8217;s (MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the overall weakness in the economy. It has affected sales adversely in recent quarters. The competition confronting Myriad Genetics&#8217; products in the biotechnology and genetics testing field is also a concern. Consequently, we downgrade the stock to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/23/mygn-myriad-genetics-bear-of-the-day-2/37635/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Signs Deal With Japan-Based Takeda Pharmaceutical Company</title>
		<link>http://www.stockbloghub.com/2010/04/06/amag-amag-pharmaceuticals-signs-deal-with-japan-based-takeda-pharmaceutical-company/32916</link>
		<comments>http://www.stockbloghub.com/2010/04/06/amag-amag-pharmaceuticals-signs-deal-with-japan-based-takeda-pharmaceutical-company/32916#comments</comments>
		<pubDate>Tue, 06 Apr 2010 20:46:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3SBio Inc]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[IDA]]></category>
		<category><![CDATA[IdaCorp]]></category>
		<category><![CDATA[SSRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32916</guid>
		<description><![CDATA[Recently, AMAG Pharmaceuticals Inc. (AMAG) and Japan-based Takeda Pharmaceutical Co. Ltd. entered into a license, development and commercialization deal related to AMAG’s Feraheme (ferumoxytol) injection for intravenous (IV) use across all potential indications for the drug. Feraheme is an intravenous iron-replacement therapy for fighting anemia in patients with chronic kidney disease (CKD). The drug can be used by patients irrespective of dialysis. The deal, potentially worth $280 million, will grant Takeda rights to sell its anemia drug in some overseas markets. Specifically, the deal provides Takeda the rights to market Feraheme in Europe, the Commonwealth of Independent States, Canada, Turkey, and the Asia-Pacific region apart from China, Japan, and Taiwan. Under the terms of the agreement, AMAG will receive an upfront payment of $60 million. Furthermore, the Massachusetts-based company will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/amag-amag-pharmaceuticals-signs-deal-with-japan-based-takeda-pharmaceutical-company/32916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/04/01/abax-abaxis-analyst-maintains-neutral-rating/32639</link>
		<comments>http://www.stockbloghub.com/2010/04/01/abax-abaxis-analyst-maintains-neutral-rating/32639#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:48:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32639</guid>
		<description><![CDATA[We recently reiterated our ‘Neutral’ rating on Abaxis, Inc. (ABAX) with a target price of $28, based on a P/E of 34.1x our fiscal 2011 EPS estimate of 82 cents. Abaxis’ results for the third quarter fiscal 2010 were mixed. Earnings per share for the third quarter was 15 cents, below the Zacks Consensus Estimate of 17 cents. However, earnings was flat on a year-over-year basis. Total revenue in the third quarter increased 15% year over year to $31 million, fueled by higher instrument unit sales. Revenues from instrument sales and consumables increased 6% and 20% year over year, respectively, in the third quarter. Total medical and veterinary instrument sales increased 37% year over year to 1,212 units. In terms of customer group: Veterinary market sales increased 33% year over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/abax-abaxis-analyst-maintains-neutral-rating/32639/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Third Quarter Earnings Meets Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/04/01/blud-immucor-third-quarter-earnings-meets-consensus-estimates/32583</link>
		<comments>http://www.stockbloghub.com/2010/04/01/blud-immucor-third-quarter-earnings-meets-consensus-estimates/32583#comments</comments>
		<pubDate>Thu, 01 Apr 2010 16:39:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32583</guid>
		<description><![CDATA[Immucor Inc. (BLUD) announced third quarter 2010 (ending in Feb 2010) earnings per share (EPS) of 28 cents, in line with the Zacks Consensus Estimate and a penny higher than the year ago quarter. Net income for the quarter was $20.1 million, compared with $19.5 million for the same quarter in 2009. The company reported $80.5 million in revenues, an increase of 7% from $75.3 million in the year-ago period. The increase in revenues was primarily based on price increases and a positive impact of $1.8 million due to foreign exchange fluctuations. Volume contribution from reagents was negatively impacted by fewer shipping cycles in the current year as well as sales mix. While Immucor has recorded growth in its top line, its gross margin suffered due to costs related to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/blud-immucor-third-quarter-earnings-meets-consensus-estimates/32583/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NEOG) Neogen&#8217;s Earnings Inches Past Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/31/neog-neogens-earnings-inches-past-estimates/32390</link>
		<comments>http://www.stockbloghub.com/2010/03/31/neog-neogens-earnings-inches-past-estimates/32390#comments</comments>
		<pubDate>Wed, 31 Mar 2010 20:48:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NEOG]]></category>
		<category><![CDATA[Neogen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32390</guid>
		<description><![CDATA[Neogen Corp. (NEOG) posted fiscal 2010 third-quarter results on Monday. The company’s net income recorded a strong growth of 37.5% to $3.9 million, or 17 cents per share from $2.8 million, or 12 cents per share in the year-ago period. The result also squeezed past the Zacks Consensus Estimate of 16 cents and was primarily driven by robust sales of food safety test kits. Neogen develops and markets products dedicated to food and animal safety. The company&#8217;s Food Safety division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen&#8217;s Animal Safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. The Lansing, MI-based Neogen witnessed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/neog-neogens-earnings-inches-past-estimates/32390/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Third Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/03/29/blud-immucor-third-quarter-2010-earnings-preview/31748</link>
		<comments>http://www.stockbloghub.com/2010/03/29/blud-immucor-third-quarter-2010-earnings-preview/31748#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:21:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31748</guid>
		<description><![CDATA[Immucor (BLUD) is scheduled to report its third quarter fiscal 2010 results on March 31, 2010. The Zacks Consensus Estimate for the quarter is pegged at a profit of 28 cents. Going by past trends, Immucor has surpassed expectations in the past four quarters. The company had a positive surprise of 20% and 7.69% in the first and second quarters of fiscal 2010, respectively, with a positive four-quarter average of 19.13%. This means that, on an average, the company has topped the Zacks Consensus Estimate by 19.13% over the last four quarters. If third quarter earnings meet our expectation, it will represent a 3.7% year-over-year growth. Immucor’s main products – traditional reagents, capture reagents and instruments have recorded robust growth in the past few quarters, a trend we expect to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/blud-immucor-third-quarter-2010-earnings-preview/31748/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Analysts Upgrades the Stock to Neutral</title>
		<link>http://www.stockbloghub.com/2010/03/27/srdx-surmodics-analysts-upgrades-the-stock-to-neutral/31557</link>
		<comments>http://www.stockbloghub.com/2010/03/27/srdx-surmodics-analysts-upgrades-the-stock-to-neutral/31557#comments</comments>
		<pubDate>Sat, 27 Mar 2010 21:12:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31557</guid>
		<description><![CDATA[We have recently upgraded our recommendation on SurModics (SRDX) to Neutral. During the first quarter of 2010, the company’s earnings per share (EPS) came in at 24 cents, surpassing the Zacks Consensus Estimate by 5 cents. Although revenues of $21 million were down 26% from the year-ago period, it was primarily due to the termination of the company’s agreement with Merck (MRK) in September 2008. SurModics derives a substantial portion of its drug delivery revenue from the Cypher stent, which is marketed by Johnson &#38; Johnson’s (JNJ) Cordis division. Despite severe competition in the stent market, revenues from the cardiovascular segment during the quarter recorded a 9% sequential growth. This segment accounted for 62% of total revenues. In addition, we are pleased to note that the overall drug-eluting stent penetration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/srdx-surmodics-analysts-upgrades-the-stock-to-neutral/31557/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VIVO) Meridian Bioscience Slashes Outlook For 2010</title>
		<link>http://www.stockbloghub.com/2010/03/19/vivo-meridian-bioscience-slashes-outlook-for-2010/31303</link>
		<comments>http://www.stockbloghub.com/2010/03/19/vivo-meridian-bioscience-slashes-outlook-for-2010/31303#comments</comments>
		<pubDate>Fri, 19 Mar 2010 22:14:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[VIVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31303</guid>
		<description><![CDATA[Life science company, Meridian Bioscience, Inc. (VIVO), recently slashed its outlook for fiscal 2010 (ending Sep 30, 2010) mainly due to a weaker-than-expected H1N1 season and lower C. difficile product revenues. The company now expects net sales in the range of $145 million &#8211; $153 million in fiscal 2010, down from the earlier guidance of $160 million &#8211; $165 million. Meridian expects earnings in the range of 70 - 80 cents, down significantly from the previous guidance of 90 - 95 cents. Following the guidance revision by the company, the Zacks Consensus Estimate for fiscal 2010 has gone down to 75 cents, well below the earlier estimate of 93 cents. Meridian also provided guidance for the second quarter of fiscal 2010. The company expects to deliver earnings in the range of 13 - ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/vivo-meridian-bioscience-slashes-outlook-for-2010/31303/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Reports Narrower Fourth Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/03/03/amag-amag-pharmaceuticals-reports-narrower-fourth-quarter-loss/29463</link>
		<comments>http://www.stockbloghub.com/2010/03/03/amag-amag-pharmaceuticals-reports-narrower-fourth-quarter-loss/29463#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:47:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3SBio Inc]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[SSRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29463</guid>
		<description><![CDATA[AMAG Pharmaceuticals Inc. (AMAG) reported a fourth-quarter fiscal 2009 net loss of $18.4 million, or $1.07 per share, which was lower than the year-ago loss of $21.8 million, or $1.28. The Zacks Consensus Estimate for the reported quarter was a loss of $1.08. The lower loss in the quarter was attributable to higher revenues following the approval and subsequent launch of the Feraheme injection. The higher revenue in the quarter more than offset the higher operating costs and expenses in the quarter attributable to increased selling, general and administrative expenses incurred for the commercialization of Feraheme. Revenue for the reported quarter came in at $13.1 million as opposed to $0.6 million in the year-ago period. Net product revenues of Feraheme stood at $12.8 million in the reported quarter Incorporatedluding $1.3 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/amag-amag-pharmaceuticals-reports-narrower-fourth-quarter-loss/29463/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Surpasses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/04/mygn-myriad-surpasses-consensus-estimates/26894</link>
		<comments>http://www.stockbloghub.com/2010/02/04/mygn-myriad-surpasses-consensus-estimates/26894#comments</comments>
		<pubDate>Thu, 04 Feb 2010 22:59:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26894</guid>
		<description><![CDATA[Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago earnings were inclusive of a loss of $15.6 million from discontinued operations pertaining to Myriad’s former research and pharmaceutical businesses. Detailed Quarterly Results Myriad posted a net profit of $35.4 million, which represented a 67% rise from the year-ago quarter. This increase in profitability was attributable to the company’s improved gross profit margin in the reported quarter of 88% as against 87% in the first quarter of fiscal 2010. Molecular diagnostic revenues for the quarter came in at $92.8 million as against $84.0 million in the prior-year quarter, a 10.5% increase. The improvement was attributable primarily ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/04/mygn-myriad-surpasses-consensus-estimates/26894/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/01/abax-abaxis-thurd-quarter-2010-report-misses-estimates/26569</link>
		<comments>http://www.stockbloghub.com/2010/02/01/abax-abaxis-thurd-quarter-2010-report-misses-estimates/26569#comments</comments>
		<pubDate>Mon, 01 Feb 2010 18:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26569</guid>
		<description><![CDATA[Abaxis, Inc. (ABAX) reported third quarter fiscal 2010 earnings per share of 15 cents, missing the Zacks Consensus Estimate of 17 cents. However, earnings in the year-ago quarter were 15 cents. Sales Total revenues in the third quarter increased 15% year over year to $31.0 million, fueled by higher instrument unit sales. Revenues from instrument sales and consumables increased 6% and 20% year over year, respectively, in the third quarter. Total medical and veterinary instrument sales increased 37% year over year to 1,212 units. In terms of customer group: Veterinary market sales increased 33% year over year to $23.9 million due to higher veterinary reagent disc sales. Medical market sales declined 28% year over year to $5.2 million primarily due to a decline in instrument sales to the U.S. government ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/01/abax-abaxis-thurd-quarter-2010-report-misses-estimates/26569/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Earnings Report Beats Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/29/srdx-surmodics-earnings-report-beats-expectations/26442</link>
		<comments>http://www.stockbloghub.com/2010/01/29/srdx-surmodics-earnings-report-beats-expectations/26442#comments</comments>
		<pubDate>Sat, 30 Jan 2010 01:15:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26442</guid>
		<description><![CDATA[SurModics (SRDX) reported first quarter fiscal 2010 earnings per share (EPS) of 11 cents, down from $1.53 in the year ago period. However, after adjustments, the EPS of 24 cents surpassed the Zacks Consensus Estimate by 5 cents. The company reported revenues of $17.4 million, down 72.5% from the corresponding period last year. The primary reason for the decline was the termination of the company’s agreement with Merck (MRK). Revenues were down 9% on a sequential basis. SurModics opened a new cGMP facility in Alabama. The facility is expected to generate revenues for the company from the second quarter. The major portion of capital investment for this facility has already been made with another $3 million?$4 million expected to be spent on equipment in the remainder of fiscal 2010. In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/srdx-surmodics-earnings-report-beats-expectations/26442/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VIVO) Meridian Bioscience Misses Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/01/23/vivo-meridian-bioscience-misses-expectations-by-a-penny/25758</link>
		<comments>http://www.stockbloghub.com/2010/01/23/vivo-meridian-bioscience-misses-expectations-by-a-penny/25758#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:29:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[VIVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25758</guid>
		<description><![CDATA[Recently, Meridian Bioscience Inc. (VIVO) reported results for the first quarter of fiscal 2010. The company earned 22 cents per share in the quarter which fell short of the Zacks Consensus Estimate by a penny. Meridian Bioscience earned 20 cents per share in the year-ago quarter. Net sales for the quarter came in at $42.45 million as opposed to $34.29 million in the prior-year quarter, up 24%. Segment-wise, sales from its U.S. Diagnostics unit came in at $30.70 million as opposed to $23.48 million in the year-ago quarter, up 30.8%. The European Diagnostics division registered sales of $6.29 million in the quarter compared to $5.67 million in the year-ago quarter, up 10.9%. The Life Science unit came up with quarterly sales of $5.46 million as against $5.14 million in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/vivo-meridian-bioscience-misses-expectations-by-a-penny/25758/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Receives FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/01/23/abax-abaxis-receives-fda-approval/25762</link>
		<comments>http://www.stockbloghub.com/2010/01/23/abax-abaxis-receives-fda-approval/25762#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:14:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25762</guid>
		<description><![CDATA[Abaxis, Inc. (ABAX) recently received the U.S. Food and Drug Administration (FDA) approval to market its new C-Reactive Protein (CRP) assay in the United States. The new C-Reactive Protein assay is used by healthcare professionals in conjunction with Abaxis’ Piccolo Xpress point-of-care analyzer to conduct on-site chemistry analysis for conditions like infections, inflammatory diseases, tissue injury and few neoplastic processes. The on-site chemistry analysis takes only twelve minutes to complete the process. It has been seen so that CRP is generally used by Rheumatologists in the detection and treatment of Rheumatoid Arthritis. In addition, the CRP test can be used in the detection and treatment of other afflictions like Colon Cancer, Non Hodgkin&#8217;s Lymphoma, Atrial fibrillation, fever from bacterial infections, and Osteomyelitis. The new product is an addition to Abaxis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/abax-abaxis-receives-fda-approval/25762/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Guides on Feraheme</title>
		<link>http://www.stockbloghub.com/2010/01/12/amag-amag-pharmaceuticals-guides-on-feraheme/24690</link>
		<comments>http://www.stockbloghub.com/2010/01/12/amag-amag-pharmaceuticals-guides-on-feraheme/24690#comments</comments>
		<pubDate>Tue, 12 Jan 2010 23:55:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3SBio Inc]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[SSRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24690</guid>
		<description><![CDATA[Recently, AMAG Pharmaceuticals Inc. (AMAG) stated that it expects net revenues between $12 and $13 million from its lead anti-anemia injectable product Feraheme for the fourth quarter of fiscal 2009 (ended December 31). AMAG had launched the Feraheme (ferumoxytol) injection in the United States on July 13, 2009. It is an intravenous iron replacement therapy to fight anemia in patients with chronic kidney disease (CKD). The drug can be used by patients even if they are undergoing dialysis. The company further stated that Feraheme has been purchased by more than 1,000 customers to date, approximately 60% of whom have bought the drug on a repeat basis. Management believes that approximately 60% of the demand for Feraheme since its launch has come from patients not undergoing dialysis. AMAG believes that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/12/amag-amag-pharmaceuticals-guides-on-feraheme/24690/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Beats Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/08/blud-immucor-beats-earnings-estimates/24461</link>
		<comments>http://www.stockbloghub.com/2010/01/08/blud-immucor-beats-earnings-estimates/24461#comments</comments>
		<pubDate>Fri, 08 Jan 2010 20:34:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24461</guid>
		<description><![CDATA[Immucor (BLUD) announced second quarter 2010 earnings per share of 28 cents, which was better than the Zacks Consensus Estimate of 26 cents and the year-ago quarter’s 24 cents. Net income for the quarter was $19.7 million, compared with $17.3 million for the same quarter last year. The company reported $82.6 million in revenues, an increase of 13% from $73 million in the corresponding period last year. The increase in revenues was based on both price and volume contributions, as well as a positive impact of $1.9 million due to foreign exchange fluctuations. While Immucor recorded robust growth in its top line, its gross margin suffered due to costs related to the company’s Quality Process Improvement Project, targeted at establishing a better quality system. The project, expected to be completed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/blud-immucor-beats-earnings-estimates/24461/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Launches New Bird Flu Test Product</title>
		<link>http://www.stockbloghub.com/2009/12/29/abax-abaxis-launches-new-bird-flu-test-product/23868</link>
		<comments>http://www.stockbloghub.com/2009/12/29/abax-abaxis-launches-new-bird-flu-test-product/23868#comments</comments>
		<pubDate>Wed, 30 Dec 2009 01:07:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23868</guid>
		<description><![CDATA[Abaxis, Inc. (ABAX) reported that it has launched its first product, a rapid Avian Influenza Antigen Test, in the production animal diagnostics market. Avian Influenza Antigen Test is a disposable and USDA-licensed test for Avian Influenza Type A nucleoprotein antigen in chickens, turkeys and ducks. Abaxis has worldwide rights to market this product globally. Avian Influenza Antigen Test is capable of providing results in fifteen minutes. It can be performed on-field or in a laboratory of any size. Abaxis has a strong research and development team that evaluates various opportunities to leverage its intellectual property and other joint product development ventures. Including Avian Influenza Antigen Test, the company has launched four new products in different fields to date in 2009. We think that the new product will boost Abaxis’ top-line. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/abax-abaxis-launches-new-bird-flu-test-product/23868/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NEOG) Neogen Beats Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2009/12/22/neog-neogen-beats-earnings-expectations-by-a-penny/23448</link>
		<comments>http://www.stockbloghub.com/2009/12/22/neog-neogen-beats-earnings-expectations-by-a-penny/23448#comments</comments>
		<pubDate>Wed, 23 Dec 2009 01:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NEOG]]></category>
		<category><![CDATA[Neogen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23448</guid>
		<description><![CDATA[Neogen Corp. (NEOG) recently posted fiscal second quarter results. The company’s GAAP net income grew 18% to $4.6 million, compared to $3.9 million in the year-ago period. Adjusting for a 3-for-2 stock split effective Dec 15, earnings per share came in at 20 cents per share, which edged past the Zacks Consensus Estimate by a penny. Neogen develops and markets products dedicated to food and animal safety. The company&#8217;s Food Safety division markets dehydrated culture media, and diagnostic test kits to detect food borne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. Neogen&#8217;s Animal Safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. During the quarter, Neogen completed the acquisition of BioKits food safety business of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/22/neog-neogen-beats-earnings-expectations-by-a-penny/23448/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2009/12/17/mygn-myriad-genetics-upgraded-to-neutral/23104</link>
		<comments>http://www.stockbloghub.com/2009/12/17/mygn-myriad-genetics-upgraded-to-neutral/23104#comments</comments>
		<pubDate>Thu, 17 Dec 2009 18:42:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23104</guid>
		<description><![CDATA[We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics. We believe that the de-risking strategy to separate the profitable predictive medicine business from the higher risk drug development business will create better value for shareholders. Each company will be able to pursue its long-term strategic initiatives, maximize its core technology strengths, seek new product opportunities, have a capital structure appropriate for its financial profile, and compete more effectively in its respective markets. Sales of Myriad Genetics’ molecular diagnostic products continued to grow impressively in the first quarter of fiscal 2010. Sales came in at $85.1 million, versus $70.0 million for the same period ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/mygn-myriad-genetics-upgraded-to-neutral/23104/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/16/mygn-myriad-genetics-bear-of-the-day/20657</link>
		<comments>http://www.stockbloghub.com/2009/11/16/mygn-myriad-genetics-bear-of-the-day/20657#comments</comments>
		<pubDate>Mon, 16 Nov 2009 18:22:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20657</guid>
		<description><![CDATA[Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the slowdown in revenue growth in recent quarters. The competition confronting Myriad Genetics products in the biotechnology and genetics testing field is also a concern. We have an Underperform rating on the stock. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/16/mygn-myriad-genetics-bear-of-the-day/20657/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny</title>
		<link>http://www.stockbloghub.com/2009/11/08/mygn-myriad-genetics-inc-misses-forecasts-by-a-penny/19880</link>
		<comments>http://www.stockbloghub.com/2009/11/08/mygn-myriad-genetics-inc-misses-forecasts-by-a-penny/19880#comments</comments>
		<pubDate>Mon, 09 Nov 2009 03:23:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19880</guid>
		<description><![CDATA[Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the year-ago period. Molecular diagnostic revenues for the quarter came in at $85.12 million as against $69.97 million in the prior-year quarter, a 21.6% increase. The improvement was attributable mainly to Myriad&#8217;s increased sales and marketing efforts. However, revenue growth has slowed in the recent quarters due to the recession. Myriad has undertaken several measures Incorporatedluding adding new sales representatives, to reinvigorate sales. Gross profit for the quarter came in at $74.1 million, or 87% of molecular diagnostic revenues, as against $60.2 million, or 86% of molecular diagnostic revenues last year. The margin growth was primarily attributable to improvements in technology coupled with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/mygn-myriad-genetics-inc-misses-forecasts-by-a-penny/19880/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Misses Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/07/srdx-surmodics-misses-earnings-estimates/19819</link>
		<comments>http://www.stockbloghub.com/2009/11/07/srdx-surmodics-misses-earnings-estimates/19819#comments</comments>
		<pubDate>Sun, 08 Nov 2009 00:33:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19819</guid>
		<description><![CDATA[SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down 17% compared to the year ago period. In addition to quarterly results, SurModics came out with fiscal year 2009 results. The company recorded revenues of $121.5 million in 2009, up 25%, compared to $97 million in the previous year and earnings per share of $1.07 for 2009. On a business unit basis, apart from Diagnostic, revenues from the other three segments – Cardiovascular, Ophthalmology and Other Markets, recorded a decline in revenues for the fourth quarter. While Diagnostic revenues increased 2% year over year to $4.6 million, revenues for the other three segments declined 12% to $9.8 million, 29% to $1.9 million and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/07/srdx-surmodics-misses-earnings-estimates/19819/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Earnings Report Lags Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/28/abax-abaxis-earnings-report-lags-consensus-estimates/19052</link>
		<comments>http://www.stockbloghub.com/2009/10/28/abax-abaxis-earnings-report-lags-consensus-estimates/19052#comments</comments>
		<pubDate>Wed, 28 Oct 2009 22:13:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19052</guid>
		<description><![CDATA[Abaxis Inc. (ABAX) reported second quarter fiscal 2010 earnings per share of 14 cents, lower than the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 15 cents. Total revenues for the reported quarter were $30.3 million, logging a growth of 9% year over year. Growth was driven by strong medical and veterinary instrument and reagent disc sales. Medical and veterinary instrument sales grew 26% year over year to 926 units. Medical and veterinary reagent disc sales expanded 2% year over year to 1.5 million units. In terms of customer group: Medical market revenues increased 5% year over year to $6.3 million. Veterinary market revenues rose 9% year over year to roughly $21.7 million. In terms of products: Instrument sales declined 5% year-over-year due to lower average selling ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/abax-abaxis-earnings-report-lags-consensus-estimates/19052/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) Surmodics Inks Licensing Deal With Roche</title>
		<link>http://www.stockbloghub.com/2009/10/09/srdx-surmodics-inks-licensing-deal-with-roche/17337</link>
		<comments>http://www.stockbloghub.com/2009/10/09/srdx-surmodics-inks-licensing-deal-with-roche/17337#comments</comments>
		<pubDate>Fri, 09 Oct 2009 17:44:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Angiotech Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANPI]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17337</guid>
		<description><![CDATA[On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets. Under the terms of the agreement, SurModics is entitled to an up-front payment of $3.5 million. Furthermore, the deal could be worth up to $200 million in delayed payments if multiple products are successfully developed. SurModics will also receive royalties on product sales. SurModics will receive payments for its development services. Under the terms of the agreement, Roche and Genentech have the right to obtain manufacturing services from SurModics. The transaction provides Roche and Genentech complete access to the biodegradable microparticles developed by SurModics. They ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/09/srdx-surmodics-inks-licensing-deal-with-roche/17337/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Immucor Beats Estimates &#8211; Reaffirmed Fiscal 2010 Revenue and Earnings Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/06/blud-immucor-beats-estimates-reaffirmed-fiscal-2010-revenue-and-earnings-guidance/16646</link>
		<comments>http://www.stockbloghub.com/2009/10/06/blud-immucor-beats-estimates-reaffirmed-fiscal-2010-revenue-and-earnings-guidance/16646#comments</comments>
		<pubDate>Tue, 06 Oct 2009 18:41:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[Immucor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16646</guid>
		<description><![CDATA[Recently, Immucor (BLUD) announced its first quarter (ending August 2009) 2010 earnings of 30 cents, which was better than the Zacks Consensus Estimate of 25 cents and the year ago quarter’s earnings of 28 cents. Net income in the quarter was $21.3 million, compared with $20.0 million for the same quarter last year. The company reported $83.1 million in revenues, an increase of 14% from $73.2 million in the corresponding period last year. The increase in revenues was based on both price and volume contributions, partially offset by foreign exchange fluctuations. While Immucor recorded a robust growth in its top line, its gross margin suffered due to costs related to the company’s Quality Process Improvement Project, targeted at establishing a better quality system. Gross margin during the quarter declined 110 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/06/blud-immucor-beats-estimates-reaffirmed-fiscal-2010-revenue-and-earnings-guidance/16646/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISTA) ISTA Pharmaceuticals Eye Drug Gets FDA Approval</title>
		<link>http://www.stockbloghub.com/2009/09/09/ista-ista-pharmaceuticals-eye-drug-gets-fda-approval/14709</link>
		<comments>http://www.stockbloghub.com/2009/09/09/ista-ista-pharmaceuticals-eye-drug-gets-fda-approval/14709#comments</comments>
		<pubDate>Wed, 09 Sep 2009 22:24:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14709</guid>
		<description><![CDATA[Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a twice-daily prescription eye drop treatment. ISTA filed the New Drug Application for the drug (bepotastine ophthalmic solution) on Nov 13, 2008. As a reminder, the advisory committee of the FDA had recommended the drug in June. The seven-member panel had voted unanimously in favor of Bepreve after reviewing comprehensive safety and efficacy data from ISTA&#8217;s clinical program. Bepreve is expected to be available to ophthalmologists and patients in the United States in the fourth quarter of 2009. The company, which expects to recognize revenues from the drug from this ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/ista-ista-pharmaceuticals-eye-drug-gets-fda-approval/14709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISTA) ISTA Pharmaceuticals&#8217;s Eye Drug Shows Success</title>
		<link>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559</link>
		<comments>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559#comments</comments>
		<pubDate>Thu, 27 Aug 2009 19:51:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13559</guid>
		<description><![CDATA[ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post cataract surgery. The drug was also successful in eliminating eye pain one day following surgery. No serious adverse events were observed and the safety profile appeared to be consistent with the company’s twice a day Xibrom version, which has already hit the market. The U.S. marketing rights to Xibrom, which is used for the treatment of ocular inflammation following cataract surgery, were acquired by ISTA in 2002 and the product was launched in the U.S. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/ista-istas-eye-drug-shows-success/13559/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

